Article Text

PDF
AB0138 Interferon-gamma challenge of PBMC from patients with lupus nephritis in remission decreases suppressor of cytokine signaling 1 (SOCS1) and regulatory t cells (TREGS) and promotes immune activation
  1. G Gibor1,
  2. U Arad1,
  3. J Wallman1,
  4. J Ablin1,
  5. V Aloush1,
  6. I Kaufman1,
  7. S Jacky2,
  8. D Caspi1,
  9. O Elkayam1,
  10. D Paran1,
  11. A Sharabi3
  1. 1Rheumatology
  2. 2Tel Aviv Medical Center, Tel Aviv, Israel
  3. 3Harvard BIDMC, Boston MA, United States

Abstract

Background Interferon-gamma (IFN-γ) plays an important role in the development of lupus nephritis (LN). Regulation of IFN-γ signaling that occurs in disease remission and in active LN is herein addressed.

Objectives To study the impact of IFN-γ on PBMC obtained from patients with LN in remission as compared to active LN.

Methods Sixteen patients fulfilling the ACR classification criteria for systemic lupus erythematosus were recruited. All patients had a history of LN of whom 10 were in remission (as defined by EULAR criteria) and 6 had active LN (as defined by SLEDAI-2K or BILAG). Healthy subjects (n=10) were included as a control group. Sera and PBMC were obtained from each individual. Flow cytometry, western blots and real time RT-PCR were used in processing and detection of cell subtypes, protein and mRNA levels. Recombinant human IFN-γ (rhIFN-γ) and anti-IFN-γ neutralizing antibody were used in vitro. Mann-Whitney and student t-tests were used for statistical analysis.

Results In active LN there was a significant 2-fold increase in CD4+CD69+ activated T cells as compared to healthy subjects and patients in remission. Reactivity to interferon-gamma receptor was determined by the phosphorylation of its predominant transcription factor, signal transducer and activator of transcription 1 (STAT1) in the cells that were incubated with rhIFN-γ or with media alone. In active LN, 3- and 6-fold increase in pSTAT1 occurred with rhIFN-γ incubation during 24h and 48h, respectively, and healthy subjects responded likewise. In patients in remission, pSTAT1 increase was even higher (by 8- and 10-fold at 24h and 48h, respectively). After 24h incubation with rhIFN-g all groups had elevated (mRNA) expression of SOCS1, but at 48h, it significantly decreased in healthy subjects and in patients in remission by 34% and 50%, respectively. Further, at 24h the frequency of CD4+CD127lowFoxP3+ regulatory T cells (e.g. Tregs) increased by 27–30% in active LN and in healthy subjects, and in remission it was minimally changed. At 48h, the frequency of Tregs significantly decreased in healthy subjects (to baseline levels before rhIFN-γ challenge) and in patients in remission (by 24%, p=0.003). A challenge of PBMC from LN patients in remission with sera (at 1% concentration) derived from patients with active LN resulted in 7.5-fold increase in pSTAT1 expression and 20–30% decrease in Tregs, however, combination of sera and anti-IFN-g neutralizing antibody resulted in 5-fold decrease in pSTAT1 expression and significantly diminished the decrease in Tregs.

Conclusions In LN in remission a challenge with IFN-γ could lead to immune activation and a risk of flare-up, as it results in a decrease in both SOCS1 and Tregs and a robust STAT1 phosphorylation. In active LN, STAT1 phosphorylation is less diminishing, as both SOCS1 and Tregs are saturated, which could affect their suppressive effectiveness.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.